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ABSTRACT 
 The association between serum bile acid levels and preterm birth has been 
reported. Clinical studies have shown that significant increase of serum bile acids 
during intrahepatic cholestasis of pregnancy (ICP) is associated with higher rate of 
preterm birth. However, the role of bile acids in preterm birth has not been established. 
In this study, we found that preterm birth was induced in mice by increasing plasma 
bile acids with cholic acid (CA) or carbon tetrachloride (CCl4) treatment. CCl4 
treatment increased plasma bile acids by causing acute liver injury which down-
regulated bile salt export pump (BSEP) in the liver. The data demonstrated that 
increased bile acid levels served as trigger for preterm birth.  Consistent with the 
findings, reducing plasma bile acids by cholestyramine (CTM) was able to reverse the 
preterm birth induced by CA by decreasing plasma bile acid levels.fds 
Mechanistic investigation revealed that preterm delivery induced by elevated 
bile acids was mediated by prostaglandins and prostaglandin receptor expressions. An 
increase in prostaglandin F2α receptor (PTGFR) and a decrease in 15-
hydroxyprostaglandin dehydrogenase (HPGD) and prostaglandin E2 receptor 
(PTGER2), all of which participate in normal parturition, was observed. More 
importantly, the expression change in PTGFR was reversed with CTM treatment, 
suggesting that prostaglandin F2α (PGF2α)/PTGFR signaling pathways are involved in 
mediating preterm birth induced by bile acids. Further studies showed an inverse 
correlation between plasma progesterone (P4) levels and PTGFR expression, which is 
consistent with significant P4 withdrawal and elevation of PTGFR before delivery in 
human. 
  
 In conclusion, we established the causative relationship of maternal bile acid 
levels and preterm delivery. The results from this study provide a molecular basis for 
new strategies to prevent preterm birth in pregnant women with ICP or other liver 
diseases by modulating bile acid homeostasis as well as the PGF2α/PTGFR signaling 
pathways.   
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1. INTRODUCTION 
 Preterm birth is the greatest contributor to infant death. The shorter the term of 
pregnancy, the greater the risks of morbidity and mortality due to prematurity. Preterm 
birth accounts for 10% of neonatal mortality worldwide, 25% in the US, and surviving 
premature infants are at risk for neurological, cardiovascular, respiratory or metabolic 
complications (Matthew & MacDorman, 2006). Despite many efforts to understand the 
timing of parturition, the molecular mechanism is still not fully understood (Mesiano & 
Welsh, 2007; Chan, 2014). 
 Spontaneous preterm birth is one of the most common fetal complications of 
intrahepatic cholestasis of pregnancy (ICP), which occurs in about 19 to 60% of cases 
(Bacq et al., 1997; Fisk & Storey, 1988). One of the hallmark signs of ICP is elevation 
of serum bile acids due to impaired disposition of bile acids from the liver. Once 
maternal serum total bile acids (TBA) levels exceed 10 µmol/L, the patient is diagnosed 
as ICP. Severity of ICP is classified based on maternal serum TBA level. Serum TBA 
level of 10 to 39 µmol/L corresponds to mild, 40 to 99 µmol/L to moderate, and ≥ 100 
µmol/L to severe ICP. Even with current treatments, spontaneous preterm birth occurs 
more than twice in ICP compared to normal pregnancies, and the incidences of fetal 
demise ranges from 2 to 11% (Geenes et al., 2014; Pata et al., 2011). The largest 
prospective cohort study in severe ICP to date concluded that risks for adverse perinatal 
outcomes including preterm delivery and stillbirth are significantly higher in severe ICP 
(Geenes et al., 2014). 
 Additional evidence connects the severity of the ICP conditions and timing of 
parturition. According to a study conducted in Sweden, risks of spontaneous preterm 
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birth and other fetal complications increase 1 to 2% for every additional µmol/L of 
maternal serum bile acids when it is ≥ 40 µmol/L (Glantz, Marschall & Mattsson, 2004). 
Another study conducted in San Francisco, CA concluded that severe ICP is associated 
with increased fetal complications (Rook et al., 2012). 
The mechanism to trigger spontaneous preterm birth has not been fully 
understood. Evidence shows the association of elevated maternal serum TBA with 
preterm birth (Geenes et al., 2014; Glantz, Marschall & Mattsson, 2004; Rook et al., 
2012). From these, it is reasonable to speculate that maternal serum TBA may play an 
important role in signaling preterm birth. However, currently there have been no studies 
to fully understand the role of bile acids in preterm birth. From this, we hypothesized 
that increase in serum bile acids play a direct role in inducing preterm labor.  
In this study, we observed that direct treatment with bile acids in mice elevated 
maternal plasma bile acids and induced preterm labor. Treatments with hepatotoxin was 
also associated with preterm labor while increasing plasma bile acid levels from liver 
damage. In addition, preterm labor induced by elevated plasma bile acids was 
successfully reversed when plasma bile acid levels were decreased by bile acid 
sequestrant. The data demonstrated that elevation of plasma bile acids is a contributing 
factor in triggering preterm labor. 
To study the mechanisms by which bile acids signal preterm labor, we 
investigated the changes in parturition-associated gene expressions in uteri following 
bile acid treatment. Changes in target gene expression revealed the involvement of 
prostaglandin signaling pathways in preterm labor. Understanding the pathological 
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mechanisms by which bile acids affect parturition will ultimately provide a molecular 
basis for development of new strategies to prevent preterm birth. 
 
1.1 Review of Literature 
Hormonal, Genetic, and Environmental Effect on ICP and Bile Acids 
 ICP patients have a defect in excretion of bile salts, which leads to increased 
serum bile acids. However, the pathophysiology of ICP is still unclear. Suggested 
mechanisms of ICP have three different factors – hormonal, genetic, and environmental 
effects. Increase in sex hormone levels during the later stages of pregnancy, genetic 
mutations and drug-induced liver injury have been studied as contributing factors for 
ICP (Reyes & Simon, 1993; Floreani & Gervasi, 2016; Paternosteer et al., 2002). 
Although these three factors pose different mechanistic pathway, all results in increased 
serum bile acids. 
 During late stages of pregnancy, sex hormones, mainly estrogens and 
progesterone, increase. This increase may slow normal flow of bile acids out of the liver 
by inhibiting bile salt export pump (BSEP, ABCB11) or multidrug resistance protein 3 
(MDR3, ABCB4), which result in accumulation of bile acids in the liver and increased 
serum TBA levels (Stieger, Fattinger, Madon, Kullak-Ublick & Meier, 2000; Debry, 
Nash, Neklason & Metherall, 1997). The estradiol/estrogen receptor alpha 
transrepressive pathway directly interacts with farnesoid-X receptor (FXR) signaling 
pathway to reduce hepatic excretion of bile acid by inhibiting BSEP, which is positively 
regulated by bile acids/FXR signaling pathway (Chen et al., 2015; Song et al., 2014). 
Consistently, increase in estrogen and estrogen metabolites has been shown to cause 
cholestasis in animals (Stieger, Fattinger, Madon, Kullak-Ublick & Meier, 2000). 
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 Progesterone level is also suggested to have a correlation with ICP. Progesterone 
treatment during third trimester resulted in development of ICP in some cases 
(Lammert, Marschall, Glantz & Matern, 2000). Progesterone metabolites, particularly 
sulfated form, are increased in ICP patients more than unaffected women (Reyes & 
Sjovall, 2000). High levels of 3α-sulfated progesterone metabolite epillopregnanolone 
sulfate (PM5S) inhibits bile acids/FXR mediated MDR3 and FXR itself. Decrease in 
FXR expression results in reduction of BSEP expression, which leads to excessive 
accumulation of hepatic as well as serum bile acids (Abu-Hayyeh et al., 2013). 
Hormone levels are increased in twin or multiplet pregnancies, which contribute 
to 5 times higher incidence of ICP than singleton pregnancies (Gonzalez et al., 1989). 
This increase in sex hormones and their metabolites is resolved quickly after delivery 
when placental hormone production ceases, which is consistent with ICP resolving 
quickly after delivery. Based on this data, it can be concluded that sex hormone levels 
are closely related to increasing serum bile acid levels for development and resolution 
of ICP. 
ICP patients may also present with elevated bile acids from genetic mutations. 
One of the risk factors for ICP is personal or family history (Abu-Hayyeh, 
Papacleovoulou & Williamson, 2013). Patients with a personal history of ICP present 
with 70% higher risk of developing ICP in subsequent pregnancies. In addition, ICP 
extends in families (Lammert, Marschall, Glantz & Matern, 2000; Reyes, 1992). It has 
been studied that many of ICP patients carry mutations in ABCB11 and/or ABCB4 
gene. Those who possess p.V444A BSEP polymorphism were significantly at higher 
risk for developing in ICP (Meier et al, 2008; Dixon et al, 2009). Heterozygous p.G855R 
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mutation in BSEP can also increase sensitivity to estrogen to induce cholestasis or 
impair bile acid secretion from the liver, which result in increased serum bile acids 
(Reyes & Simon, 1993; Lang et al, 2007). Prevalence of ICP also depends greatly on 
geographic regions. ICP incidence rate ranges from 0.1% to 15.6% worldwide, showing 
higher prevalence in South America (especially Chile and Bolivia) or Scandinavia 
(Reyes et al., 1978). Even within the US, the rate of ICP in pregnancy ranges from 
0.32% in Bridgeport Hospital, CT to 5.6% in Los Angeles where a majority are Latin 
population (Laifer, Stiller, Siddiqui, Dunston-Boone, & Whetham, 2001; Lee, 
Goodwin, Greenspoon, & Incerpi, 2006). These statistics suggest that genetic difference 
among races is also a contributing factor in development of ICP (Geenes & Williamson, 
2009).  
In addition to hormonal and genetic factors, some environmental factors may 
contribute to development of ICP (Hay, 2008; Lammert, Marschall, Glantz & Matern, 
2000). ICP can be induced by drugs that cause liver damage, which is consistent with 
statistics that ICP occurs in higher rates in pregnant women with history of liver damage 
(Guntupalli & Steingrub, 2005; Rigby, Ehrenberg-Buchner, & VanBuren, 2014). 
Hormone replacement therapy or oral contraceptive usages have also been shown to 
cause cholestasis in some cases (Reyes & Simon, 1993; O’Donohue & Williams, 1997; 
Lindberg, 1992). Additionally, in vitro fertilization or advanced maternal age can 
increase the risk for developing ICP (Geenes & Williamson, 2009). 
These three factors all contribute towards development of ICP, with common 
outcome of elevated bile acids. 
Bile Acids and Parturition 
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A study has been published which showed higher rate of spontaneous preterm 
birth when serum bile acid levels were severely elevated in ICP (Geenes et al., 2014). 
Even during normal pregnancy, bile acid levels increase as the pregnancy progresses, 
reaching its maximum during third trimester and quickly returning back to normal upon 
delivery (Castaño et al., 2006; Heikkinen, Mäentausta, Ylöstalo & Jänne, 1981). During 
ICP, cholic acid (CA) levels are more significantly increased, which leads to marked 
elevation of CA/chenodeoxycholic acid (CDCA) ratio compared to normal pregnant 
women (Meng et al., 1997). Serum CA and CDCA levels are increased ten- and five-
fold, respectively, in ICP patients (Heikkinen, Mäentausta, Ylöstalo, & Jänne, 1981). 
The average concentration of serum TBA is 7.44 µmol/L in normal pregnancy and 65.7 
µmol/L in ICP. Table 1 lists the composition of each bile acids (CA, CDCA, 
deoxycholic acid (DCA), lithocholic acid (LCA) and ursodeoxycholic acid (UDCA)) in 
TBA pool. Although CDCA, DCA, LCA, and UDCA present with slight or moderate 
increases during ICP, the extent is not as significant as CA, which is why CA is the 
choice of bile acids in inducing preterm birth in this study. 
Hepatic Capacity and Preterm Birth 
ICP incidences are more prevalent in patients with compromised liver function 
with acute or chronic liver diseases, and the outcomes to both mother and fetus are 
usually more severe (Guntupalli & Steingrub, 2005; Rigby, Ehrenberg-Buchner, & 
VanBuren, 2014). Either from genetic predisposition or from exposure to environmental 
factors, compromised functional capacity of liver results in increased serum bile acids 
(Bove et al., 2000). This further supports the relationship between elevated serum bile 
acids and preterm birth. 
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Parturition-Associated Genes 
Parturition is commonly considered as an inflammatory process (Christiaens et 
al., 2008). Up-regulation of inflammatory genes such as interleukin-6 (IL-6), 
interleukin-1β (IL1β), tumor necrosis factor alpha (TNFα) or cyclooxygenase 2 (COX2) 
have been observed during parturition and also serve as biological markers for 
spontaneous preterm birth (Menon et al., 2011; Wei, Fraser, & Luo, 2011; Paternoster 
et al., 2002).  
Some contraction-associated proteins (CAPs) such as oxytocin receptor 
(OXTR), prostaglandin E2 receptor (PTGER2), prostaglandin F receptor (PTGFR), and 
hydroxyprostaglandin dehydrogenase (HPGD) are also involved in spontaneous 
preterm birth (Soloff et al., 1983; Dong & Yallampalli, 2000). Progesterone is 
occasionally used to prevent contraction in normal pregnancies. When administered, 
progesterone inhibits OXTR and PTGFR expression to minimize myometrial 
contractility by desensitizing oxytocin and prostaglandin F2 receptors. Progesterone 
also increases HPGD expression to inactivate prostaglandins in myometrium to prevent 
contraction (Challis, Patel, & Pomini, 1999). This is consistent with normal pregnancy 
in which the onset of labor is preceded by a fall in progesterone levels. 
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2. MATERIALS AND METHODS 
2.1 Chemicals and Reagents 
 Cholic acid (CA), carbon tetrachloride (CCl4), cholestyramine (CTM), olive oil, 
chloroform, and isopropanol were purchased from Sigma-Aldrich. 1,2-propanediol was 
purchased from Acros Organics. Taqman Real-Time PCR Master Mix, RT-PCR probes, 
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12) and fetal 
bovine serum (FBS) were purchased from Life Technologies. RNA-Bee for RNA 
isolation and dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific. Total 
bile acids (TBA) assay kit (Enzymatic Cycling, Cat #. BQ 042A-EALD) and aspartate 
aminotransferase (AST/SGOT) activity assay kit (Cat #. BQ K753-100) were purchased 
from BQ kit. Estradiol ELISA kit (Cat #. 582251) and Progesterone ELISA assay kit 
(Cat #. 582601) were purchased from Cayman Chemicals. Complementary DNA 
synthesis kits were purchased from Promega. 
2.2 Timed Mating for CD-1 Mice 
 To ensure the time of treatment, mice were set up for timed mating. Mice at the 
age of two to six months old were used for mating. Two or three females and one male 
were placed in the same cage overnight. Females were checked for presence of vaginal 
plug the next morning as a confirmation of sexual activity before removing males from 
the cage. The first day of gestation was considered to be the day after the plug was 
found. 
2.3 CA Treatment of Pregnant CD-1 Mice 
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 Once the pregnancy was confirmed, pregnant mice were housed individually in 
each cage. The mice had free access to food and water and were on a 12-hour dark/light 
cycle. Twenty-four pregnant mice were randomly divided into three different groups of 
negative control, 86 mg/kg CA and 129 mg/kg CA. Nine mice were treated with 1,2-
propanediol vehicle, 6 mice were treated with 86 mg/kg CA and 9 mice were treated 
with 129 mg/kg CA. The difference in number of mice in each group were due to 
limitations in timed pregnancy of mice. The two treatment groups of mice were injected 
in the intraperitoneal cavity with a dose of 129 mg/kg CA or 86 mg/kg CA, and the 
control group was injected with 1,2-propanediol, each administered every 12 hours for 
up to 4 injections. The end of the pregnancy term was determined when pregnant mice 
started the parturition process by visibly evaluating for signs of labor such as loss of 
blood, weight loss, presence of litters, or behavior changes for pushing. To evaluate for 
cannibalism, the weight of each mouse was monitored during the injection period.  
 When the parturition process was initiated, blood samples were collected in 
EDTA-treated anticoagulant tubes via cardiac puncture under isoflurane-induced 
anesthesia and spun at 3,500g for 9 min for plasma collection. Mice were euthanized by 
cervical dislocation and liver, uterus, placenta, and ovary were harvested for further 
studies. For mice that did not develop preterm labor, blood, liver, uterus, placenta and 
ovary samples were collected on day 18.7. 
 In addition, 6 additional pregnant mice were treated as control group with 1,2-
propanediol every 12 hours for 4 injections. These mice were not sacrificed on day 18.7 
and was observed for the full-term gestation period of control mice. 
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All animal studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) at the University of Rhode Island. 
2.4 CCl4 Treatment of CD-1 Mice 
 Once pregnancy was confirmed, five, six and five pregnant females were 
injected in the peritoneal cavity with 1, 1.5 and 2 ml/kg CCl4 in olive oil (40% v/v) once 
on day 16.3, respectively. The end of the pregnancy term was determined when pregnant 
mice started the parturition process by visibly evaluating for signs of labor. Mice were 
monitored for weight changes during injection period, and blood and tissue samples 
were harvested as previously described. 
2.5 Plasma Total Bile Acids (TBA) Assay 
After isolation of plasma from collected blood, four microliters of plasma were 
added to 270 µL of reagent R1. The mixture was then incubated at 37ºC for 3 minutes. 
After incubation, ninety microliters of reagent R2 were added to the mixture and the 
absorbance was immediately monitored at 405 nm for 2 minutes. ∆A405 nm/min was 
calculated for each sample and concentrations of TBA were calculated compared to the 
standard provided in the kit. 
2.6 Plasma Aspartate Transaminase (AST/SGOT) Assay 
AST reagent provided in the kit was reconstituted with 12 mL of distilled water. 
The reagent was then equilibrated to 37ºC. Ten microliters of plasma sample were 
mixed with 100 µL of reconstituted AST reagent. The absorbance was measured at 340 
nm every minute for 3 minutes while the mixture was maintained at 37ºC. 
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∆A340nm/min was calculated for each sample and concentrations of AST were 
calculated based on sample volume and instrument specification. 
2.7 Plasma Progesterone (P4) ELISA Assay 
Enzyme immunoassay (EIA) buffer, wash buffer, P4 tracer, P4 antiserum, 
Ellman’s reagent and P4 standards were reconstituted per kit protocol. Each run 
included wells for blank, total activity, non-specific binding, maximum binding (B0), 8 
standards, and samples (B). For non-specific binding, a hundred microliters of EIA 
buffer and 50 µL of tracer were added to a well of ELISA plate coated with mouse 
monoclonal anti-rabbit IgG. For maximum binding, fifty microliters of EIA buffer, 50 
µL of tracer, and 50 µL of antiserum were added. For each samples and standards, 50 
µL of plasma or standard solution, 50 µL of tracer, and 50 µL of antiserum were added. 
Once all the reagents were added, the plate was incubated at room temperature for an 
hour on orbital shaker. After the incubation, the plate was washed with wash buffer for 
five times and 200 µL of Ellman’s reagent was added to each well. For total activity, 
five microliters of tracer was added. Then the plate was incubated at room temperature 
for 90 minutes on orbital shaker. After the incubation, plate was read at 405 nm. 
 Standard curve was plotted for %B/B0 of standards vs. log of standard 
concentrations, and was fitted using 4-parameter logistic fit. Curve fitting was 
performed on SigmaPlot. Concentrations of P4 in each sample were calculated 
according to the logistic fit parameters. 
2.8 Mouse Tissue mRNA Isolation and Quantitative Real-Time Polymerase Chain 
Reaction (RT-PCR) Analysis 
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Mouse liver, uterus or placenta was homogenized in 1 mL of RNA-Bee per 50 
mg of tissue for mRNA extraction. Three hundred microliters of chloroform was added 
per 1 mL of each homogenate, and the mixture was shaken vigorously for 30 seconds, 
followed by 5-minute incubation on ice. Samples were centrifuged at 12,000g for 15 
minutes and the supernatant was mixed with 0.5 mL isopropanol in a clean tube. 
Samples were incubated at room temperature for 10 minutes and spun at 12,000g for 
five minutes. The supernatant was discarded. The remaining pellet was washed with 
70% ethanol in diethylpyrocarbonate (DEPC)-treated water and was spun at 7,500g for 
five minutes. The washing step was repeated once to improve the quality of mRNA. 
The supernatant was then discarded and the pellet was dried under the air for 20-30 
minutes until the pellet turned clear/opaque. The dried pellet was dissolved in 150 µL 
of DEPC-treated water at 4ºC overnight. RNA was quantified on Nano-Drop and 2.5 µg 
of total RNA was used for reverse transcription into complementary DNA (cDNA). 
ViiA 7 Real-Time PCR System (Thermo Fisher Scientific) was used for Taqman RT-
PCR. Using relative quantification (RQ) of cycle thresholds for each sample, transcript 
levels of each gene were normalized against the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). 
2.9 Cholestyramine (CTM) Treatment for CA or CCl4-Induced Preterm Labor 
CTM diet was prepared by mixing 2.5% (w/w) CTM resin in the regular diet. 
Twelve pregnant females were injected in the peritoneal cavity with 86 mg/kg CA in 
1,2-propanediol every 12 hours for up to four injections. CTM diet was started 24 hours 
prior to the first injection. The end of the pregnancy term was determined when pregnant 
mice started the parturition process. Daily food consumption was monitored. Treated 
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mice were observed for weight and behavioral changes, and organs were harvested as 
previously described. To evaluate for cannibalism, the weight of each mouse was 
monitored during injection period. 
2.10 E2 Treatment on Pregnant CD-1 Mice 
 Four pregnant female mice were injected in the peritoneal cavity with 5 mg/kg 
of E2 in 1,2-propanediol every 12 hours starting on day 15.7 for six consecutive 
injections. The end of the pregnancy term was determined when pregnant mice started 
the parturition process by visibly evaluating for signs of labor. Mice were monitored for 
weight or behavioral changes, and organs were collected as previously described for 
mRNA determination. 
2.11 Treatment of Human Myometrial Cells (hTERT-HM) 
The hTERT-HM human myometrial cell line was kindly provided by Dr. Jennifer 
Condon (University of Pittsburgh, Pittsburgh, PA) and was maintained in DMEM/F12 
supplemented with 10% FBS and 1% penicillin/streptomycin at 37ºC under humidifient 
5% CO2 and 95% air. 
 hTERT-HM cells were seeded in 10-cm petri dish in 10 mL phenol-red free 
DMEM/F12 supplemented with 10% (v/v) charcoal-stripped FBS and 1% (v/v) 
penicillin/streptomycin and cultured under 5% CO2 until cells reached 75% confluency. 
Once the desired confluency was achieved, growth medium was replaced with 10 mL 
of phenol-red free DMEM/F12 supplemented with 1% (v/v) charcoal-stripped FBS and 
1% (v/v) penicillin/streptomycin. Cells were then treated with 0.2% ethanol and 0.2% 
DMSO for controls or with 10, 50, 100, or 200 µM of CA in DMSO. Wells treated with 
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CA also received treatment with 100 nM of E2 in ethanol and 1 µM of P4 in ethanol to 
mimic pregnancy condition. 
 Progesterone-alone treatment was carried out in cell plates prepared as above. 
Cells were treated with 0.1% ethanol for control or with 200 nM, 1, 5, 10, and 50 µM 
of P4 in ethanol. All treatments were 0.1% of total volume medium. 
2.12 Statistical Analysis 
Welch’s t-test with unequal variance was applied for comparison between two 
different groups. Grubbs’ test was applied to detect any outliers within each groups. The 
values of outliers were repeated at least three times and confirmed. Standard deviation 
was used as the measure of variability. A p-value of less than 0.05 was considered 
statistically significant. MS Excel, Prism GraphPad or SigmaPlot were used for 
statistical analysis.  
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3. RESULTS 
3.1 CA-Induced Preterm Labor 
 In order to test our hypothesis that bile acids cause preterm labor, pregnant 
mice were treated with CA and were observed for any preterm labor. CA was used to 
increase maternal TBA as it is most significantly increased form of bile acids in ICP 
(Table. 1). The first injection of CA was on day 16.3 of gestation based on ICP 
presentation, which correlates with elevation of bile acids in the last trimester of 
gestation (Brites, 2002).   
To verify elevation of plasma TBA following CA injection, TBA 
concentrations in plasma were measured in CA-injected mice. The results showed 
significant increase in plasma TBA at the time of labor in pregnant mice treated with 
86 mg/kg CA (20.7 ± 8.0 µM, p = 0.0044) and 129 mg/kg CA (29.7 ± 13.6 µM, p = 
0.0008) compared to those treated with vehicle (6.73 ± 3.04 µM; Figure 1A). CA 
injection also resulted in an elevated plasma AST level; however, only high dose CA 
significantly increased AST at the time of labor (17.3±8.7 vs. 52.7±23.9 IU/L, p = 
0.002; Figure 1B). This suggested that higher dose of CA treatment exerted mild liver 
injury due to overload of bile acids. In addition, higher dose of CA treatment resulted 
in higher rates of stillbirth than preterm labor. Therefore, lower dose CA treatment that 
did not show any toxicity to the liver with no risk for inducing stillbirth was used for 
further experiments. 
Average full pregnancy term for normal CD-1 mice was 19.9 days, 95% CI 
[19.6, 20.1]. With CA treatment, gestation period was significantly decreased 
compared to vehicle treated mice (Figure 1C). Mice treated with 86 mg/kg CA had an 
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average term of 18.3 days (95% CI [18.2, 18.4]) and mice treated with 129 mg/kg CA 
had an average term of 17.8 days (95% CI [17.6, 18.0]; p < 0.00005 for both). Based 
on the results, it was established that direct CA treatment to intraperitoneal cavity of 
mice was able to induce preterm labor. 
Changes in sex hormone levels were observed following CA treatment. Plasma 
P4 concentrations at the time of labor were significantly decreased from 20.1 ± 13.6 
ng/ml in vehicle-treated mice to 0.34 ± 0.23 ng/ml and 2.39 ± 1.14 ng/ml in mice 
treated with 86 mg/kg and 129 mg/kg CA, respectively (p = 0.002 and 0.005; Fig. 1D). 
The result from this study is consistent with the changes in plasma P4 level in rodents 
during pregnancy, which maintains high progesterone level before delivery with a 
sudden decline once subjects initiate the labor. In addition, depending on the stage of 
labor, level of progesterone greatly differ. This may explain the wide variability in 
mice in control group. 
In all plasma analysis, sample #4 in 86 mg/kg CA treatment group and sample 
#8 in 129 mg/kg CA treatment group showed abnormal values for both TBA and P4 
assay, and were identified as outliers by Grubbs’ test. These samples were excluded 
from the plasma analyses. Figures including these two samples are depicted in Fig 1. 
 The data collectively demonstrates that CA treatment to pregnant mice in the 
late stages of pregnancy elevated plasma bile acids without causing liver toxicity (low 
dose CA) and contributed to inducing preterm labor.  
3.2 CCl4-induced Preterm Labor 
 ICP is often accompanied by liver injuries, and risk of ICP increases in those 
who have previous or pre-existing liver damage (Guntupalli & Steingrub, 2005). As 
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liver injuries are accompanied by elevated bile acids, the effect of acute liver toxicity 
by CCl4 in the length of pregnancy term was investigated. CCl4 is one of the most 
potent hepatotoxins and is commonly used to induce acute liver injury in rodents 
(Mehendale, 1984; Mehendale et al., 1994). In treatments with varying concentrations 
of CCl4, early parturition was achieved in 67%, 83.3%, and 100% of subjects treated 
with 1 ml/kg, 1.5 ml/kg, and 2ml/kg of 40% (v/v) CCl4 in olive oil, respectively 
(Figure 2A). Compared to full term, mice treated with 1 ml/kg CCl4 solution had an 
average pregnancy term of 18.9 days (95% CI [18.4, 19.4]; p = 0.07), mice treated 
with 1.5 ml/kg CCl4 had an average term of 18.1 days (95% CI [17.9, 18.4]; p = 
0.0002), and mice treated with 2 ml/kg CCl4 had an average term of 17.6 days (95% 
CI [17.3, 17.9]; p < 0.00005). Although the highest dose showed 100% shorter term 
delivery, 90% of the litters were stillbirth. The lower two doses had 12% stillbirth with 
1.5ml/kg CCl4, and 4.8% stillbirth with 1 ml/kg CCl4. Stillbirth or perinatal death in 
ICP occurs in about 2 to 11% of pregnancies, which is not the majority (Ehrenberg-
Buchner & VanBuren, 2014). Therefore, the dose of 1.5 ml/kg of CCl4 was used in 
future mouse studies. 
 To confirm CCl4 induced acute hepatotoxicity, plasma AST levels at the time 
of labor were evaluated. As shown in Figure 3B, significant increases of serum AST 
levels were detected in pregnant mice treated with CCl4 compared with those who 
received vehicle treatment (17.3 ± 8.7 vs. 111.2 ± 19.6 IU/L, p = 0.00003), verifying 
acute liver damage by CCl4. Acute liver injury in turn was correlated with increase in 
plasma TBA. Figure 3C showed elevation of plasma TBA with CCl4 treatment (6.73 ± 
3.0 vs. 22.7 ± 6.2 µM, p = 0.0003). These results indicated that limiting liver 
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metabolic capacity induced preterm labor with increasing plasma TBA from acute 
hepatotoxicity. 
 Plasma P4 concentrations at the time of labor were decreased with CCl4 
treatment (6.37 ± 5.7 ng/mL, p = 0.02; Fig. 3D) as compared to those treated with 
vehicle (20.1 ± 13.6 ng/ml). This result was consistent with the P4 level change in 
CA-induced preterm labor, which the mice in labor showed significantly decreased 
plasma concentration of P4. 
 The data collectively demonstrated that CCl4 treatment to pregnant mice in the 
late stages of pregnancy effectively increased plasma TBA by inducing acute liver 
toxicity, which likely contributed to triggering preterm labor, and showed 
progesterone withdrawal during preterm labor.   
3.3 Changes in Gene Expressions in the Uterus for CA- or CCl4-Induced Preterm 
Labor 
 With confirmation of preterm labor by elevated bile acids from treatments with 
CA or CCl4, multiple parturition-associated genes in the uterus that have a role in 
delivery mechanism were analyzed for changes in expressions by real-time RT-PCR. 
Control samples were collected at the same time on day 18.7. However, samples in 
control group had not begun the parturition process, which adds to the limitation by 
comparing them with samples collected during labor for CA or CCl4 treatment groups. 
Treatments of pregnant mice with CA or CCl4 significantly increased OXTR mRNA 
expression by 2.7 and 2.0 fold, respectively (p = 0.004 and 0.04; Fig. 3A). Oxytocin is 
a hormone that causes contraction of the uterus, and OXTR, which encodes its 
receptor, is up-regulated during parturition (Blanks & Thornton, 2003). Our finding is 
 19 
 
in agreement with reported evidence of increased OXTR expression during labor. It 
has been suggested that IL-6 plays a role in the regulation of onset of labor by 
increasing expression of genes that control prostaglandin synthesis (Robertson et al., 
2010). Our data showed a significant increase of IL-6 expression by 17 fold in mice 
treated with CA (p = 0.044; Fig. 3B). In mice treated with CCl4, IL-6 levels exhibited 
a trend of increase but did not reach statistical significance (p = 0.14; Fig. 3B). Sample 
#1 from CCl4 treatment group was identified as an outlier for IL-6 expression, 
possibly due to pre-existing liver damage as spotty liver was observed during organ 
collection. The result including this data point is shown in figure 3B-1. Prostaglandin 
(PG) F2α is known to play a major role in triggering parturition as a contractile PG, 
with increased expression of PTGFR as pregnancy term progresses (Brody-Eppley & 
Myatt, 1998). In this study, we found that PTGFR expression levels at parturition were 
significantly elevated by 1.5 and 2.1 fold in mice treated with CA and CCl4, 
respectively (p = 0.049 and 0.040; Fig. 3C). On the other hand, the expression of 
HPGD, a major enzyme to metabolize prostaglandins, was significantly down-
regulated by both CA and CCl4 treatments compared to control group. The expression 
levels of HPGD were decreased by 49% and 77% in mice treated with CA and CCl4 (p 
= 0.0006 and p < 0.00005; Fig. 3D). The existing data suggest elevated prostaglandin 
levels during parturition due to decreased prostaglandin metabolism (Challis, Patel, & 
Pomini, 1999). Our data is in agreement with the evidence which prostaglandin levels 
during parturition is elevated due to decreased prostaglandin metabolism by HPGD. 
We also found that PTGER2 expression was decreased with CA and CCl4 treatment 
by 45% and 68%, respectively (p = 0.043 and 0.0065; Fig. 3E). It has been known that 
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PGE2 is a relaxatory prostaglandin during labor, and its receptor is decreased before 
and after the labor (Brodt-Eppley & Myatt, 1998). Taken together, decreased 
expression of PTGER2 and HPGD with concurrent increased expression of PTGFR in 
mice treated with CA and CCl4 support the notion that labor process is mediated by 
prostaglandins and that CA-induced preterm labor undergoes the similar mechanism to 
labor in normal pregnancy. No consistent significant changes were observed for TNFα 
and COX2 with either CA or CCl4 treatment (Fig. 3F, 3G). This result indicates that 
preterm labor induced by CA and CCl4 may not involve other cytokines, as COX2 
participates in synthesis of cytokines other than prostaglandins as well. Conclusively, 
all the data suggest that prostaglandin is closely related to preterm labor by CA or 
CCl4 treatment. Further investigation of gene changes in full term labor is in need to 
claim whether the prostaglandins mediate the preterm labor or the parturition mediates 
the change in prostaglandin-associated genes. 
3.4 Changes in Gene Expressions in the Liver of Mice with CA- or CCl4-Induced 
Preterm Labor 
 In order to investigate the mechanisms of bile acid elevation and prostaglandin 
metabolism in mice with CA or CCl4 treatment, BSEP, FXR and HPGD expressions 
in the liver were quantified by RT-PCR. As seen in figure 4A, no significant changes 
were observed for FXR after either treatment. However, with CCl4 treatment, BSEP 
expression was significantly down-regulated by 81% (p < 0.0003; Fig. 4B). The 
results indicated that down-regulation of BSEP in the liver following CCl4 treatment 
was a mechanism for increased plasma TBA by inhibiting hepatic bile acids excretion. 
Also, HPGD expression in the liver was down-regulated by 31% and 49% with 
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treatments with CA or CCl4, respectively (p = 0.04 and 0.0022; Fig. 4C). This result 
suggest that systemic prostaglandin level is also decreased during labor due to 
decreased metabolism of prostaglandin in the liver, which is the major site for 
prostaglandin metabolism. In summary, the results suggest that CA and CCl4 induced 
preterm labor is associated with inhibition of systemic prostaglandin metabolism and 
inhibition of BSEP in the liver by CCl4 to increase plasma TBA. 
3.5 Reversal of Preterm Labor in CA-treated Pregnant Mice by CTM 
 In order to confirm if preterm labor was truly triggered by elevation of plasma 
TBA, cholestyramine, a bile acid binding resin, was investigated to possibly reverse 
preterm labor. Cholestyramine is a bile acid sequestrant which forms insoluble 
complex with bile acids in the gastrointestinal tract to prevent reabsorption of bile 
acids. By administering cholestyramine, plasma TBA was expected to decrease and 
CA-induced preterm labor to be reversed if bile acid is truly the triggering factor. 
 CTM was added to diet simultaneously with CA injection, as previously 
described, to 12 pregnant females in the later stages of pregnancy. Preterm labor was 
reversed by 50% in mice treated with CA and CTM in comparison with mice treated 
with CA injection alone. More importantly, the reversibility of preterm labor by CTM 
was correlated with the amounts of CTM consumption of individual mouse. Of 12 
mice given CTM diet and CA injection, the six that did not have preterm labor 
consumed significantly more food compared to the six that had preterm labor (6.76 ± 
1.92 g vs. 2.65 ± 1.74 g over 72 hours, p = 0.003; Fig. 5A). Among six mice that had 
preterm labor with CA and CTM co-treatment, it was observed that the less CTM diet 
consumption, the gestation period was shorter (R2 = 0.97; Fig. 5B). As expected, the 
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mice who consumed more CTM had decreased TBA levels (6.06 ± 3.03 µM) than the 
mice who consumed less CTM (17.9 ± 14.8 µM, p = 0.056; Fig. 5C). Taken together, 
the reversibility of preterm labor by CTM was directly correlated with the amount of 
food consumed and the resulting TBA levels. In all further analyses, tissue and plasma 
samples were performed only on the six mice that did not have preterm labor. 
In the treatment with CTM, mice that did not have preterm labor, there was a 
decrease in plasma TBA to normal level (6.06 ± 3.03 µM) compared to TBA levels in 
mice that had CA-treated preterm labor (20.7 ±8.0 µM, p = 0.004; Fig. 6A). There 
were no significant changes in plasma AST (Fig. 6B), which indicates that CTM 
treatment did not exhibit liver toxicity. Plasma P4 level was also increased by 74 fold 
compared to CA-alone treatment (0.34 ± 0.23 vs. 25.12 ± 20.08 ng/mL, p = 0.03; Fig. 
6C). Taken together, the plasma levels of TBA, AST and P4 of CTM treated full-term 
mice were compatible to that of regular full-term mice. The data indicated that by 
directly lowering plasma TBA, risk of preterm labor was reversed, which further 
strengthen the notion that elevated bile acids are the triggering factors in inducing 
preterm labor. 
 Consistently, RT-PCR revealed reversed trends in target genes compared to 
CA treatment. Samples were collected at the time of labor throughout the day. CTM 
treatment group samples that did not have preterm labor were collected uniformly at 
day 18.7 before initiation of parturition. The mRNA expression of OXTR was 
decreased by 51% in mice that had reversed preterm labor from CTM diet (p = 0.014; 
Fig. 7A). IL-6 expression showed a decreasing trend on average by 87% with CA and 
CTM treatment without statistical significance, which is consistent with the trend 
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when comparing with normal pregnancy (Fig. 7B). PTGFR was decreased by 56% 
compared to CA alone (p = 0.0067; Fig. 7C), and HPGD expression showed 1.7 fold 
increase (p = 0.027; Fig. 7D). The changes in expression of HPGD and PTGFR with 
CA treatment were reversed with CTM comparable to normal level, indicating that 
increase in PG level and PTGFR expression may play a more important role in 
initiation of labor process. COX2, which showed an increasing trend but did not have 
a statistically significant change with CA treated preterm-term mice compared to 
vehicle, was significantly decreased with CTM treatment (2.64 vs. 0.27, p = 0.04; Fig. 
7E). Since COX2 participates in synthesizing prostaglandins, we expect that synthesis 
of prostaglandins would be decreased by decreasing plasma TBA. CTM treatment was 
able to reverse some changes in parturition-associated gene expressions by CA 
treatment. The results collectively indicated that CA-induced preterm labor was 
reversed by decreasing plasma TBA levels with CTM, while showing down-regulated 
PTGFR expression and possibly prostaglandin synthesis. 
Collectively, the results demonstrate that CTM was able to effectively prevent 
preterm labor induced by elevation of bile acids. It can be expected that once constant 
delivery of CTM is guaranteed, complete prevention of preterm labor is possible. 
3.6 Bile Acids for Appetite Suppression 
 Although this was not the purpose of our study, we had an interesting 
discovery while monitoring the food consumption of CA or CCl4 treated mouse.  
During pregnancy, food intake is increased in humans. The same principle applies for 
mice. In the control group, pregnant female mice at later stage of pregnancy had 
average food consumption over 24 hours of 7.25 g. However, with CA or CCl4 
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treatment, the diet pattern was altered. After CA injection, average food consumption 
over 24 hours was decreased to 2.44 g (p < 0.00001, Fig. 8A). With CCl4 injection, 
average food consumption was decreased to 1.55 g over 24 hours (p < 0.00001, Fig. 
8B). This was a rather surprising finding that diet intake was decreased with elevated 
TBA, to even lower than average intake for non-pregnant mice (4-5 g). This finding is 
consistent with previous publications which demonstrated appetite suppression effects 
of CDCA and DCA (George & Gallagher, 1968; Roberts et al., 2011). Decreased 
appetite in CCl4-treated mice may be due to increased plasma TBA. 
 In addition to decreased diet intake, it was also noted that CA or CCl4 
treatment in pregnant mice were associated with no weight gain or slight weight loss. 
Typically during pregnancy, both mouse and human gain weight as the term 
progresses. We observed that in late stages of pregnancy, mice usually gain 1 – 3 g of 
weight every day. However, during the course of our study, we noticed that pregnant 
mice treated with CA or CCl4 had either no change in weight or losing 1 – 2 g daily. 
This may be due to reduced food intake as described above. 
3.7 Effect of E2 on TBA and AST 
 Previous studies have established that estrogen-induced cholestasis occurs by 
altering expression of BSEP (Song et al., 2014). To further investigate the effect of 
estrogen in increasing bile acids to trigger preterm labor, four pregnant females 
received 5 mg/kg E2 treatment every 12 hours starting day 15.7. Indeed, E2 treatment 
elevated plasma TBA from 6.73 µM to 14.8 µM (p = 0.007; Fig. 9A). However, E2 
treatment did not cause preterm labor in any subjects. It should be noted that although 
bile acids were elevated in E2-treated mice, the levels were still lower than that in 
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mice treated with CA or CCl4. Consistent with mild increase in TBA, no significant 
changes were observed for plasma AST level and P4 levels (Fig. 9B and 9C). Whether 
increasing E2 doses to further elevate bile acid levels will induce preterm labor 
remains to be determined.  
 Change in mRNA expression levels of target genes on day 18.7 was analyzed 
by RT-PCR. E2 treatment resulted in non-significant increase of OXTR expression by 
2.2 fold (p = 0.072; Fig. 10A). Since these mice did not have preterm labor, OXTR 
expression was not expected to change much. IL-6 expression in uterus was 
significantly increased with E2 treatment by 9.7 fold, which indicates that E2 
treatment contributes to increasing cytokines other than prostaglandins (p = 0.015; 
Fig. 10B). PTGFR expression, unlike mice treated with CA or CCl4, was down-
regulated by 52% (p = 0.01; Fig. 10C). Consistently with the change in CA or CCl4 
treated mice, HPGD expression level in E2 treated mice was decreased by 29% (p = 
0.044; Fig. 10D). Similar changes in trends of OXTR, IL-6 and HPGD but not in 
PTGFR occurred with exposure to CA or CCl4 treatment suggest that preterm labor 
may be more affected by expression level of PTGFR. COX2 mRNA expression level 
was decreased with E2 treatment by 90% (p = 0.0008; Fig. 10E), suggesting that E2 
treatment contributed in decreasing synthesis of cytokines including prostaglandin. 
The results collectively indicate that elevation of E2 alone may not be 
sufficient enough to trigger preterm labor. Although serum TBA is elevated, the 
magnitude of increase for E2 treated mice is 1.5-2 fold less than that for CA or CCl4 
treated mice. In addition, E2 treatment did not induce expected trend for PTGFR. 
Although prostaglandin metabolism was decreased by decreased HPGD expression, 
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PTGFR was significantly down-regulated, even compared to control. From the 
discrepancy in gene expression changes in PTGFR compared to mice that had preterm 
labor and all previous results of expression changes in prostaglandin-regulating genes, 
we suggest prostaglandin F2α/PTGFR signaling pathway is the determinant factor in 
triggering preterm delivery. 
3.8 Bile Acids and Sex Hormone Treatments in Human Myometrial Cell Line 
(hTERT-HM) 
 To further confirm the correlation of current data to human, expression 
changes in target genes in hTERT-HM myometrial cells were investigated. First, cells 
were treated with varying concentrations of P4 to determine a dose-response 
relationship. As concentration of P4 treatment increased, OXTR was decreased (Fig. 
11A) and IL-6 (Fig. 11B) and COX2 (Fig. 11C) were increased. 
 Cells were treated with varying concentrations of CA to study the effect of CA 
on target genes, while mimicking pregnancy condition with concurrent E2 and P4 
treatment. E2 and P4 concentrations were chosen based on their effect on hTERT-HM 
cell individually. One millimolar of P4 was used in this treatment since this 
concentration did not cause any changes in expression of OXTR, IL-6 and COX2 by 
P4 itself. The result showed that as concentrations of CA were increased, all three 
targets – OXTR (Fig. 12A), IL-6 (Fig. 12B) and COX2 (Fig. 12C) – were increased. 
The data suggest that CA treatment in presence of E2 and P4 increase inflammatory 
genes. However, PTGFR, which was the target gene of our study, did not show any 
significant change with either P4 or CA with sex hormones combination treatment. 
HPGD was not even detectable in this specific cell line. 
 27 
 
 These results coincide with that from the in vivo experiment where P4 surge 
was associated with lower OXTR expression and increase in serum TBA caused 
elevation of OXTR, IL-6 and COX2. However, due to the discrepancy in PTGFR and 
HPGD expression, this cell might not be suitable for further investigation for our 
study. The effect of bile acids on endometrial cell line should be investigated in order 
to study more accurate mechanism of preterm labor induced by bile acids.  
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4. DISCUSSION 
 In this study, we successfully established the cause-effect relationship between 
bile acids and preterm labor. Elevation of bile acids was achieved by either direct 
introduction of CA or by inducing acute hepatotoxicity with CCl4. The results of this 
study provided direct evidence to support the findings in several publications that 
severely elevated maternal serum bile acids were linked to higher rate of preterm birth 
and fetal complications (Geenes et al., 2014; Rigby, Ehrenbery-Buchner, & VanBuren, 
2014; Glantz, Marschall, & Mattsson, 2004).  
Treatments with CA or CCl4 showed increase in several parturition-associated 
genes including OXTR, IL-6, and PTGFR, and decrease in HPGD and PTGER2, 
which confirms the involvement of these particular genes in preterm labor induced by 
bile acids.  
 Estrogen is known to increase bile acids. Our previous study demonstrated that 
estrogen induced cholestasis through transrepressive pathway with FXR inhibiting 
BSEP (Song et al., 2014). The results from this study showed no preterm labor with 
E2 treatment alone despite elevation of plasma TBA. However, it should be noted that 
the bile acid levels in E2-treated mice did not reach the levels observed in mice treated 
with CA or CCl4. In addition, there is a discrepancy in gene expressions between E2 
treated mice and mice that had preterm labor. Although OXTR, IL-6 and HPGD 
showed the same trend as CA or CCl4 treatment, PTGFR and COX2 were down-
regulated by E2 treatment compared to control. Collectively, we suspect that the role 
of prostaglandin F2α/PTGFR signaling pathway in parturition is critical in inducing 
preterm labor. 
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Prostaglandins are important mediators for inducing labor by uterine 
contraction (Challis & Olson, 1988; Chan, 1983; Romero et al., 1996). It is often used 
to chemically induce labor. Especially, contractile PTGFR and relaxatory PTGER2 
play the major role in uterine contractility (Coleman, Smith & Narumiya, 1994). 
Evidence supports that PTGFR expression was significantly increased until delivery 
and PTGER2 expression was significantly decreased from day 16 until postpartum in 
rats (Brody-Eppley & Myatt, 1998). Our results support this existing evidence in mice 
and suggests correlations of these receptors and bile acids in inducing labor. 
PGF2α also play an important role in progesterone level. Increases in PGF2α 
metabolites is correlated with rapid decrease in progesterone during menstrual cycle 
(Koullapis & Collins, 1980). Also in mares, progesterone treatments reversed abortion 
induced by exogenous PGF2α synthetic analog and inhibited endogenous PGF2α 
secretion (Daels et al., 1996). PG-induced contraction in swine was reduced with 
progesterone administration (Künzel et al., 2014). Progesterone, specifically 17α-
hydroxyprogesterone, is sometimes used to delay or prevent preterm labor in humans 
(Errol & Caughey, 2011). Our data showed a decrease in progesterone after initiation 
of parturition. For mice that did not have preterm labor maintained progesterone surge, 
whereas in mice that had preterm labor had a 10-15 fold decrease in plasma P4 
compared to normal or CTM treated full term mice. This shows the same trend as 
previously published evidence of inverse correlation between progesterone and PGF2α, 
as bile acids induced preterm labor in our study was also associated with increased 
expression of PTGFR and decreased P4 concentration. This also explains why E2-
treated mice did not have preterm labor despite elevation of bile acid level, since they 
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had significantly higher progesterone level even compared to control and down-
regulated PTGFR expression. With our new data, we can conclude that a primary 
mechanism to trigger bile acids induced preterm labor, and possibly all other 
parturition, is mediated by the PGF2α/PTGFR signaling pathway. Elevation of bile 
acids alone may not be sufficient enough to induce preterm labor if there is still 
progesterone surge or up-regulation of PTGFR. 
These changes in gene expression match the results from human myometrial 
cell treatment. Treatments with CA, E2 and P4 showed CA dose-response increase in 
OXTR, IL-6, and COX2 which further confirms the same effects of bile acids in 
humans. Further study to assess the translation of these gene changes in protein level 
is necessary. 
 Currently, treatment for ICP is to provide mostly symptomatic relief for 
mother. There are no conclusive results of the effects of treatment agents on 
improving fetal outcome. CTM is a bile acid sequestrant which is one of the first-line 
treatments for ICP. By directly removing bile acids in circulation, CTM relieves 
severe pruritus in ICP. Our study showed that CTM reversed 50% of CA-induced 
preterm labor by decreasing serum TBA with a strong positive relationship between 
amount of CTM intake and reversibility of preterm labor. Had 50% of mice that had 
preterm labor consumed more diet containing CTM, their preterm labor may have 
been reversed as well. Changes in expression for OXTR, IL-6, PTGFR and HPGD 
were also reversed compared to CA treatment alone. This further supports our 
hypothesis of bile acids directly related to causing preterm labor. 
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 CCl4 treatment in pregnant mice elevated plasma TBA by down-regulating 
BSEP expression in the liver. This information could be applied in preventing preterm 
labor in those who have liver injuries. Modifying BSEP expression may decrease the 
plasma TBA and could decrease risk of preterm labor. 
During the course of our study, we noticed the unusual change in weight of 
pregnant mice treated with CA or CCl4. Instead of gaining weight in the late stages of 
pregnancy, these treatments showed no weight gain or slight loss of weight in subjects. 
We suspected that this was due to excess bile acids. CDCA and DCA are known to 
suppress appetite (Bray & Gallagher, 1968; Roberts et al., 2011). Our results showed 
decreases in food intake with CA treatment compared to control in both during 
pregnancy and non-pregnancy. Although not conclusive, we suspect the relationship 
between increased plasma TBA and decreased appetite. 
There are few limitations present in this study. When comparing the changes in 
parturition-associated gene expressions, samples were compared regardless of if the 
mice were actively in labor or before labor. Therefore, we cannot conclude that these 
changes in expression are due to preterm labor by CA treatment or due to the labor 
process itself. Further investigation with in vitro model is necessary to determine the 
mechanism of bile acids on these genes. Also the samples were collected throughout 
the day as they show signs of preterm labor. As bile acids are affected by circadian 
rhythm, this might have added to the variabilities of some analyses. In addition, 
toxicity profile of CCl4 in other organs have not been fully established. Other 
chemicals such as acetaminophen should be investigated to further strengthen our 
findings that bile acids elevation due to limited liver metabolic capacity is associated 
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with preterm labor. Furthermore, as in ICP, bile acids other than CA is also elevated. 
However, this study only used CA to introduce exogenous bile acids in pregnant mice. 
For more accurate model, composite of bile acids pool should have been used.  
In conclusion, our study demonstrated that bile acids directly contribute in 
resulting in preterm labor. Although direct mechanism between bile acids and 
prostaglandin is still unclear, establishing this causative relationship may allow bile 
acids to serve as a predictor for preterm labor. Preventing spontaneous preterm birth is 
critical for fetal development in ICP. Bile acid levels serving as a biomarker for timing 
of parturition is a novel approach in studying molecular mechanism of spontaneous 
preterm labor. Understanding the pathological mechanisms by which bile acids affect 
parturition will ultimately provide a molecular basis for development of new strategies 
to prevent preterm labor. Upregulating BSEP, and decreasing bile acids, and 
antagonizing PGF2α/PTGFR signaling may represent new strategies for prevention of 
preterm labor in ICP or pregnant women with liver injuries such as cholestasis or 
hepatitis.  
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TABLES 
 
 
 Normal Pregnancy ICP 
Cholic Acid (CA) 30.4 % 2.26 µM 74.2 % 48.7 µM 
Chenodeoxycholic Acid 
(CDCA) 
40.1 % 2.98 µM 18.2 % 11.9 µM 
Deoxycholic Acid (DCA) 20.5 % 1.52 µM 6.6 % 4.34 µM 
Lithocholic Acid (LCA) 4.0 % 0.30 µM 0.5 % 0.33 µM 
Ursodeoxycholic Acid 
(UDCA) 
4.0 % 0.30 µM 0.55 % 0.36 µM 
 
Table 1. Serum bile acids composition during normal pregnancy and intrahepatic 
cholestasis of pregnancy.  
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Figure 1. Effects of CA treatment on plasma concentration of TBA, AST, P4 and 
gestation period in CD1 mice. 
 
Pregnant CD1 mice were treated with CA 86 mg/kg or 129 mg/kg in 1,2-propanediol 
or 1,2-propanediol vehicle IP. 6 mice received lower dose CA, 9 mice received higher 
dose CA or vehicle.Plasma samples were collected for TBA, AST and P4 assay. (A) 
Dose-dependent elevation of serum TBA with CA treatment, with outliers (1) and 
without outliers (2). (B) Dose-dependent elevation of serum AST with CA treatment, 
with outliers (1) and without outliers (2). (C) Shorter gestation period with CA 
treatment. (D) Decreased serum P4 with CA treatment, with outliers (1) and without 
outliers (2). (**p < 0.005, ***p < 0.001, Welch’s t-test). 
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Figure 2. Effects of CCl4 treatment on serum concentration of TBA, AST, P4 and 
gestation period in pregnant CD1 mice. 
 
Pregnant CD1 mice were treated with 1, 1.5 or 2 ml/kg of 40% (v/v) CCl4 in olive oil 
IP in 5, 6 and 5 mice per group, respectively. Plasma samples were collected for TBA, 
AST and P4 assay. (A) Dose-dependent decrease in gestation period with CCl4 
treatment. (B) Elevation of serum AST with CCl4 treatment. (C) Elevation of TBA 
with CCl4 treatment. (D) Decreased serum P4 with CCl4 treatment. (*p < 0.05, ***p < 
0.001, Welch’s t-test). 
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Figure 3. Effects of CA or CCl4 treatment on parturition-associated genes in 
uterus of CD1 mice. 
 
CD1 mice treated as above were used for mRNA analysis. Uterus were harvested 
during parturition or on day 18.7 and RNA was isolated using conditions stated in 
Materials and Methods. Endogenous OXTR (A), IL-6, with outliers (1) and without 
outliers (2) (B), PTGFR (C), HPGD (D), PTGER2 (E), TNFα (F) and COX2 (G) 
expressions were analyzed and normalized to GAPDH. The data are presented as a 
fold change in relative expression, each data points representing individual mice. (*p < 
0.05,**p < 0.005, ***p < 0.001, Welch’s t-test). 
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Figure 4. Effects of CA or CCl4 treatment on endogenous FXR, BSEP and HPGD 
in liver of CD1 mice. 
 
CD1 mice treated with CA or CCl4 as above were used for mRNA analysis. Livers 
were harvested during parturition or on day 18.7 and RNA was isolated using 
conditions stated in Materials and Methods. Endogenous FXR (A), BSEP (B) and 
HPGD (C) expressions were analyzed and normalized to GAPDH. The data are 
presented as a fold change in relative expression, each data points representing 
individual mice. (***p < 0.001, Welch’s t-test). 
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Figure 5. Effect of CTM intake amount on reversibility of preterm labor and 
plasma bile acids concentration. 
 
CD1 mice treated with CTM and CA as above were used to assess correlation between 
amount of CTM intake and reversibility of preterm labor. (A) Amount of CTM intake 
difference between groups with preterm or full term labor. (B) Dose-response 
relationship of CTM treatment and gestation period (R2 = 0.95). (C) Plasma serum 
samples were collected for determination of plasma TBA concentration. (**p < 0.005, 
Welch’s t-test). 
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Figure 6. Effects of CTM treatment on serum concentration of TBA, AST, P4 
and gestation period in CA-induced preterm labor in CD1 mice compared to 
control. 
 
Pregnant CD1 mice were treated with 86 mg/kg CA IP and given regular or CTM diet 
(6 and 12 per group, respectively). For CTM treatment, only the mice that did not have 
preterm labor was used for analyses. Control group was included to assess the 
reversibility of CTM to normal level. Plasma samples were collected for determination 
of TBA (A), AST (B) and P4 (C) concentration. (*p < 0.05,**p < 0.005, Welch’s t-
test). 
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Figure 7. Effect of CTM treatment on parturition-associated genes in uterus of 
CD1 mice. 
 
CD1 mice treated with CTM and CA as above were used for mRNA analysis. Uterus 
were harvested during parturition or on day 18.7 and RNA was isolated using 
conditions stated in Materials and Methods. Endogenous OXTR (A), IL-6 (B), 
PTGFR (C), HPGD (D) and COX2 (E) expressions were analyzed and normalized to 
GAPDH. The data are presented as a fold change in relative expression, each data 
points representing individual mice. (*p < 0.05,**p < 0.005, ***p < 0.001, Welch’s t-
test). 
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Figure 8. Effect of CA or CCl4 treatment on food consumption. 
 
Food consumption of CD1 mice treated with CA (A) or CCl4 (B) were decreased. 
Each data points represent the diet intake of CD1 mice every 24 hours after CA or 
CCl4treatment compared to normal consumption of pregnant mice. (***p < 0.001, 
Welch’s t-test). 
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Figure 9. Effects of E2 treatment on plasma concentration of TBA, AST, and P4 
in CD1 mice. 
 
Pregnant CD1 mice were treated with 5 mg/kg E2 IP. Plasma samples were collected 
on day 18.7 for determination of TBA (A), AST (B) and P4 (C) concentration. (*p < 
0.05, Welch’s t-test). 
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Figure 10. Effect of E2 treatment on parturition-associated genes in uterus of 
CD1 mice. 
 
CD1 mice treated with E2 were used for mRNA analysis. Uterus were harvested on 
day 18.7 and RNA was isolated using conditions stated in Materials and Methods. 
Endogenous OXTR (A), IL-6 (B), PTGFR (C), HPGD (D) and COX2 (E) expressions 
were analyzed and normalized to GAPDH. The data are presented as a fold change in 
relative expression, each data points representing individual mice. (*p < 0.05,**p < 
0.005, ***p < 0.001, Welch’s t-test). 
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Figure 11. Effects of P4 treatment on RNA expression of OXT, IL-6 and COX2 in 
hTERT-HM cells. 
 
hTERT-HM cells were treated with varying concentrations of P4 in ethanol or ethanol 
vehicle control. At 30 hours incubation, total RNA was isolated for RT-PCR 
quantification. The abundance of mRNA encoding OXTR (A), IL-6 (B) and COX2 
(C) in hTERT-HM cells was measured and normalized against GAPDH. The data are 
presented as fold changes in relative expression of the mean of triplicates (*p < 0.05, 
Welch’s t-test). 
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Figure 12. Effects of CA, E2 and P4 treatment on RNA expression of OXTR, IL-6 
and COX2 in hTERT-HM cells. 
 
hTERT-HM cells were treated with varying concentrations of CA in DMSO 
concurrently with consistent E2 and P4 dose in ethanol or DMSO and ethanol vehicle 
control. At 30 hours incubation, total RNA was isolated for RT-PCR quantification. 
The abundance of mRNA encoding OXTR (A), IL-6 (B) and COX2 (C) in hTERT-
HM cells was measured and normalized against GAPDH. The data are presented as 
fold changes in relative expression of the mean of triplicates (*p < 0.05, Welch’s t-
test). 
  
 50 
 
BIBLIOGRAPHY 
Abu-Hayyeh, S., Papacleovoulou, G., Lovgren-Sandblom, A., Tahir, M., Oduwole, O., 
Jamaludin, N. A., Ravat, S., Nikolova, V., Chambers, J., Selden, C., Rees, M., 
Marschall, H. U., Parker, M. G., and Williamson, C., “Intrahepatic Cholestasis 
of Pregnancy Levels of Sulfated Progesterone Metabolites Inhibit Farnesoid X 
Receptor Resulting in a Cholestatic Phenotype,” in Hepatology, 2013, pp. 716-
726. 
Abu-Hayyeh, S., Papacleovoulou, G., and Williamson, C. “Nuclear receptors, bile 
acids and cholesterol homeostasis series-bile acids and pregnancy,” in 
Molecular and Cell Endocrinology, 2013, pp. 120–128. 
Bacq, Y., Sapey, T., Bréchot, M. C., Pierre, F., Fignon, A., and Dubois, F., 
“Intrahepatic cholestasis of pregnancy: a French prospective study,” in 
Hepatology, 1997, pp. 358-364. 
Blanks, A. M., and Thornton, S., “The role of oxytocin in parturition,” in BJOG: An 
International Journal of Obstetrics and Gynaecology, Apr. 2003, pp. 46-51. 
Bove, K. E., Daugherty, C. C., Tyson, W., Mierau, G., Heubi, J. E., Balistreri, W. F., 
and Setchell, K. D., “Bile acid synthetic defects and liver disease,” in Pediatric 
and Developmental Pathology, Jan. 2000, pp. 1-16. 
Bray, G. A., and Galllagher, T. F., “Suppression of appetite by bile acids,” in The 
Lancet, 1968, pp. 1066-1067. 
Brites, D., “Intrahepatic cholestasis of pregnancy: changes in maternal-fetalbile acid 
balance and improvement by ursodeoxycholic acid,” in Annals of Hepatology, 
2002, pp. 20-28. 
Brodt-Eppley, J., and Myatt, L., “Changes in expression of contractile FP and 
relaxatory EP2 receptors in pregnant rat myometrium during late gestation, at 
labor, and postpartum,” in Biology of Reproduction, Oct. 1998, pp. 878-83. 
Challis, J. R. G., and Olson, D. M., “Parturition,” In: Knobil E, Neill J (eds.), The 
Physiology of Reproduction. New York: Random Press; 1988, pp. 2177–2284. 
Challis, J. R., Patel, F. A., and Pomini, F., “Prostaglandin dehydrogenase and the 
initiation of labor,” in Journal of Perinatal Medicne, 1999, pp. 26-34. 
Chan, R. L., “Biochemical markers of spontaneous preterm birth in asymptomatic 
women,” in Biomed Research International, 2014, pp. 164081. 
 51 
 
Chan, W. Y., “Uterine and placental prostaglandins and their modulation of oxytocin 
sensitivity and contractility in the parturient uterus,” in Biology of 
Reproduction, 1983, pp. 680–688. 
Chen, Y., Vasilenko, A., Song, X., Valanejad, L., Verma, R., You, S., Yan, B., 
Shiffka, S., Hargreaves, L., Nadolny, C., and Deng, R., “Estrogen and Estrogen 
Receptor-α-Mediated Transrepression of Bile Salt Export Pump,” in Molecular 
Endocrinology, 2015, pp. 613-626. 
Christiaens, I., Zaragoza, D. B., Guilbert, L., Robertson, S. A., Mitchell, B. F., and 
Olson, D. M., “Inflammatory processes in preterm and term parturition,” in 
Journal of Reproductive Immunology, Oct. 2008, pp. 50-57. 
Debry, P., Nash, E. A., Neklason, D. W., and Metherall, J. E., “Role of multidrug 
resistance P-glycoproteins in cholesterol esterification,” in Journal of 
Biological Chemistry, 1997, pp. 1026-1031. 
Dixon, P. H., van Mil, S. W., Chambers, J., Strautnieks, S., Thompson, R. J., 
Lammert, F., Kubitz, R., Keitel, V., Glantz, A., Mattsson, L. A., Marschall, H. 
U., Molokhia, M., Moore, G. E., Linton, K. J., and Williamson, C., 
“Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic 
cholestasis of pregnancy,” in Gut, 2009, pp. 537–544. 
Dong, Y. L., and Yallampalli, C., “Pregnancy and exogenous steroid treatments 
modulate the expression of relaxant EP(2) and contractile FP receptors in the 
rat uterus,” in Biology of Reproduction, 2000, pp. 533-539. 
Errol, N. R., and Caughey, A. B., “Progesterone supplementation and the prevention 
of preterm birth,” in Reviews in Obstetrics and Gynecology, 2011, pp. 60-72. 
Floreani, A., and Gervasi, M. T., “New Insights on Intrahepatic Cholestasis of 
Pregnancy,” in Clinical Liver Disease, Feb. 2016, pp. 177-189. 
Fisk, N. M., and Storey, G. N., “Fetal outcome in obstetric cholestasis,” in British 
Journal of Obstetrics and Gynaecology, 1988, pp. 1137-1143. 
Geenes, V., Chappell, L. C., Seed, P. T., Steer, P. J., Knight, M., and Williamson, C., 
“Association of severe intrahepatic cholestasis of pregnancy with adverse 
pregnancy outcomes: a prospective population-based case-control study,” in 
Hepatology, 2014, pp. 1482-1491. 
Geenes, V., and Williamson, C., “Intrahepatic cholestasis of pregnancy,” in World 
Journal of Gastroenterology, May. 2009, pp. 2049–2066. 
 52 
 
George, A. B., and Gallagher, T. F., “Suppression of appetite by bile acids,” in The 
Lancet, 1968, pp. 1066-1067. 
Glantz, A., Marschall, H. U., Mattsson, L. A., “Intrahepatic cholestasis of pregnancy: 
Relationships between bile acid levels and fetal complication rates,” in 
Hepatology, 2004, pp. 467-474. 
Guntupalli, S. R., and Steingrub, J., “Hepatic disease and pregnancy: An overview of 
diagnosis and management,” in Critical Care Medicine, 2005, pp. S332-S339. 
Gonzalez, M. C., Reyes, H., Arrese, M., Figueroa, D., Lorca, B., Andresen, M., 
Segovia, N., Molina, C., and Arce, S., “Intrahepatic cholestasis of pregnancy in 
twin pregnancies,” in Journal of Hepatology, 1989, pp. 84-90. 
Castaño, G., Lucangioli, S., Sookoian, S., Mesquida, M., Lemberg, A., Di Scala, 
M.,Franchi, P., Carducci, C., and Tripodi, V., “Bile acid profiles by capillary 
electrophoresis in intrahepatic cholestasis of pregnancy,” in Clinical Sciences 
(London), Apr. 2006, pp. 459-465.  
Hay, J. E., “Liver disease in pregnancy,” in Hepatology, Mar. 2008, pp. 1067-1076. 
Heikkinen, J., Mäentausta, O., Ylöstalo, P., and Jänne, O., “Changes in serum bile acid 
concentrations during normal pregnancy, in patients with intrahepatic 
cholestasis of pregnancy and in pregnant women with itching,” in British 
Journal of Obstetrics and Gynaecology, 1981, pp. 240-245.  
Künzel, J., Geisler, K., Maltaris, T., Müller, A., Hoffmann, I., Schneider, H., 
Beckmann, M. W., Dittrich, R., and Oppelt, P. G., “Effects of interactions 
between progesterone and prostaglandin on uterine contractility in a perfused 
swine uterus model,” in In Vivo, 2014, pp. 467-475. 
Laifer, S. A., Stiller, R. J., Siddiqui, D. S., Dunston-Boone, G., and Whetham, J. C., 
“Ursodeoxycholic acid for the treatment of intrahepatic cholestasis of 
pregnancy,” in Journal of Maternal-Fetal and Neonatal Medicine, 2001, pp. 
131-135. 
Lammert, F., Marschall, H. U., Glantz, A., and Matern, S., “Intrahepatic cholestasis of 
pregnancy: molecular pathogenesis, diagnosis and management,” in Journal of 
Hepatology, 2000, pp. 1012-1021. 
Lang, C., Meier, Y., Stieger, B., Beuers, U., Lang, T., Kerb, R., Kullak-Ublick, G. A., 
Meier, P. J., and Pauli-Magnus, C., “Mutations and polymorphisms in the bile 
salt export pump and the multidrug resistance protein 3 associated with drug-
 53 
 
induced liver injury,” in Pharmacogenetics and Genomics, Jan. 2007, pp. 47–
60. 
Lee, R. H., Goodwin, T. M., Greenspoon, J., and Incerpi, M., “The prevalence of 
intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles 
population,” in Journal of Perinatology, 2006, pp. 527-532. 
Lindberg, M. C., “Hepatobiliary complications of oral contraceptives,” in Journal of 
General Internal Medicine, 1992, pp. 199-209. 
Matthew, T. J., and MacDorman, M. F., “Infant mortality statistics from the 2003 
period linked birth/infant death data set,” in National Vital Statistics Reports, 
May. 2006, pp. 1-32. 
Mehendale, H. M., “Potentiation of halomethane hepatotoxicity: chlordecone 
andcarbon tetrachloride,” in Fundamental and Applied Toxicology, Jun. 1984, 
pp. 295-308. 
Mehendale, H. M., Roth, R. A., Gandolfi, A. J., Klaunig, J. E., Lemasters, J. J., and 
Curtis, L. R., “Novelmechanisms in chemically induced hepatotoxicity,” in 
Federation of American Societies for Experimental Biology Journal, Dec. 
1994, pp. 1285-1295. 
Meier, Y., Zodan, T., Lang, C.. Zimmermann, R., Kullak-Ublick, G. A., Meier, P. J., 
Stieger, B., and Pauli-Magnus, C., “Increased susceptibility for intrahepatic 
cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of 
the 1331T> C polymorphism in the bile salt export pump,” in World Journal of 
Gastroenterology, Jan. 2008, pp. 38–45. 
Meng, L. J., Reyes, H., Axelson, M., Palma, J., Hernandez, I., Ribalta, J., and Sjövall, 
J., “Progesterone metabolites and bile acids in serum of patients with 
intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy,” 
in Hepatology, 1997, pp. 1573–1579. 
Menon, R., Torloni, M. R., Voltolini, C., Torricelli, M., Merialdi, M., Betrán, A. P., 
Widmer, M., Allen, T., Davydova, I., Khodjaeva, Z., Thorsen, P., Kacerovsky, 
M., Tambor, V., Massinen, T., Nace, J., and Arora, C., “Biomarkers of 
spontaneous preterm birth: an overview of the literature in the last four 
decades,” in Reproductive Sciences, 2011, pp. 1046-1070. 
Mesiano, S., and Welsh, T. N., “Steroid hormone control of myometrial contractility 
and parturition,” in Seminars in Cell and Developmental Biology, Jun. 2007, 
pp. 321-331. 
 54 
 
O'Donohue, J., and Williams, R., “Hormone replacement therapy in women with liver 
disease,” in British Journal of Obstetrics and Gynaecology, Jan. 1997, pp.1-3. 
Pata, O., Vardareli, E., Ozcan, A., Serteser, M., Unsal, I., and Saruç, M.,  “Intrahepatic 
cholestasis of pregnancy: correlation of preterm delivery with bile acids,” in 
The Turkish Journal of Gastroenterology, Dec. 2011, pp. 602-605. 
Paternoster, D. M., Fabris, F., Palu, G., Santarossa, C., Bracciante, R., and Snijders, 
S., “Intra-hepatic cholestasis of pregnancy in hepatitis C virus infection,” in 
Acta Obstetricia Gynecologica Scandinavica , 2002, pp. 99-103. 
Paternoster, D. M., Stella, A., Gerace, P., Manganelli, F., Plebani, M., Snijders, D., 
and Nicolini, U., “Biochemical markers for the prediction of spontaneous pre-
term birth,” in International Journal of Gynaecology and Obstetrics, 2002, pp. 
123-129. 
Reyes, H., “The spectrum of liver and gastrointestinal disease seen in cholestasis of 
pregnancy,” in Gastroenterology Clinics of North America, 1992, pp. 905–921. 
Reyes, H., Gonzalez, M. C., Ribalta, J., Aburto, H., Matus, C., Schramm, G., Katz, R., 
and Medina, E., “Prevalence of intrahepatic cholestasis of pregnancy in Chile,” 
in Annals of Internal Medicine, 1978, pp. 487-493. 
Reyes, H., and Simon, F. R., “Intrahepatic cholestasis of pregnancy: an estrogen-
related disease,” in Seminars in Liver Disease, 1993, pp. 289-301. 
Reyes, H., and Sjovall, J., “Bile acids and progesterone metabolites in intrahepatic 
cholestasis of pregnancy,” in Annals of Medicine, 2000, pp. 94-106. 
Rigby, F. B., Ehrenberg-Buchner, S., and VanBuren, G. A., “Intrahepatic Cholestasis 
of Pregnancy,” in Medscape, 2014. 
Rioseco, A. J., Ivankovic, M. B., Manzur, A., Hamed, F., Kato, S. R., Parer, J. T., and 
Germain, A. M., “Intrahepatic cholestasis of pregnancy: a retrospective case-
control study of perinatal outcome,” in American Journal of Obstetrics and 
Gynecology, 1994, pp. 890-895. 
Roberts, R. E., Glicksman, C., Alaghband-Zadeh, J., Sherwood, R. A., Akuji, N., and 
le Roux, C. W., “The relationship between postprandial bile acid 
concentration, GLP-1, PYY and ghrelin,” in Clinical Endocrinology (Oxford), 
Jan. 2011, pp. 67-72. 
 55 
 
Romero, R., Munoz, H., Gomez, R., Parra, M., Polacano, M., Valverde, V., Hasburn, 
J., Garrido, J., Ghezzi, F., Mazor, M., Tolosa, J. E., and Mitchell, M. D., 
“Increase in prostaglandin bioavailability precedes the onset of human 
parturition,” in Prostaglandins, Leukotrienes and Essential Fatty Acids, 1996, 
pp. 187–191. 
Rook, M., Vargas, J., Caughey, A., Bacchetti, P., Rosenthal, P., and Bull, L., “Fetal 
outcomes in pregnancies complicated by intrahepatic cholestasis of pregnancy 
in a Northern California cohort,” in PLoS One, 2012, pp. e28343. 
Soloff, M. S., Fernstrom, M. A., Periyasamy, S., Soloff, S., Baldwin, S., and Wieder, 
M., “Regulation of oxytocin receptor concentration in rat uterine explants by 
estrogen and progesterone,” in Canadian Journal of Biochemistry and Cell 
Biology, 1983, pp. 625-630. 
Song, X., Vasilenko, A., Chen, Y., Valanejad, L., Verma, R., Yan, B., and Deng, R., 
“Transcriptional dynamics of bile salt export pump during pregnancy: 
mechanisms and implications in intrahepatic cholestasis of pregnancy,” in 
Hepatology, 2014, pp. 1993-2007. 
Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., and Meier, P. J., “Drug- 
and estrogen-induced cholestasis through inhibition of the hepatocellular bile 
salt export pump (Bsep) of rat liver,” in Gastroenterology, 2000, pp. 422-430. 
Wei, S. Q., Fraser, W., and Luo, Z. C., “Inflammatory cytokines and spontaneous 
preterm birth in asymptomatic women: a systematic review,” in Obstetrics and 
Gynecology, 2010, pp. 393-401. 
Zakar, T., and Hertelendy, F., “Progesterone withdrawal: key to parturition,” in 
American Journal of Obstetrics and Gynecology, Apr. 2007, pp. 289-296. 
 
 
 
